Xencor (XNCR) Posts Quarterly Earnings Results, Beats Estimates By $0.57 EPS

Share on StockTwits

Xencor (NASDAQ:XNCR) posted its quarterly earnings data on Monday. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.57, Fidelity Earnings reports. The company had revenue of $29.04 million during the quarter.

Shares of NASDAQ:XNCR opened at $40.33 on Wednesday. The company has a market cap of $2.12 billion, a P/E ratio of -38.41 and a beta of 1.73. Xencor has a 1-year low of $19.50 and a 1-year high of $48.38.

XNCR has been the subject of several recent analyst reports. BTIG Research initiated coverage on shares of Xencor in a report on Monday, September 10th. They issued a “buy” rating and a $56.00 price objective for the company. BidaskClub upgraded shares of Xencor from a “hold” rating to a “buy” rating in a report on Thursday, September 20th. Wedbush reiterated an “outperform” rating and issued a $42.00 price objective on shares of Xencor in a report on Monday, October 8th. Cantor Fitzgerald set a $40.00 price objective on shares of Xencor and gave the company a “buy” rating in a report on Tuesday. Finally, Piper Jaffray Companies restated an “overweight” rating on shares of Xencor in a report on Tuesday, August 7th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $41.13.

In related news, major shareholder John S. Stafford III sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, September 14th. The shares were sold at an average price of $48.05, for a total value of $48,050.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP John R. Desjarlais sold 35,000 shares of the company’s stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $40.36, for a total transaction of $1,412,600.00. The disclosure for this sale can be found here. Insiders have sold 170,624 shares of company stock valued at $7,137,684 over the last 90 days. 4.70% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Week Herald and is the sole property of of Week Herald. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://weekherald.com/2018/11/07/xencor-xncr-posts-quarterly-earnings-results-beats-estimates-by-0-57-eps.html.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Read More: Asset Allocation Models, Which is Right For You?

Earnings History for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply